Feedback
Settings

Settings

Goto Application

1. WO2022010312 - COMPOSITION COMPRISING MUC4 GENE MUTATION DETECTING AGENT FOR PREDICTION OR DIAGNOSIS OF GASTRIC CANCER

Submit observation
PermaLink
Publication Number WO/2022/010312
Publication Date 13.01.2022
International Application No. PCT/KR2021/008803
International Filing Date 09.07.2021
IPC
C12Q 1/6886 2018.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2537/165
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2537Reactions characterised by the reaction format or use of a specific feature
10the purpose or use of
165Mathematical modelling, e.g. logarithm, ratio
C12Q 2600/156
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
156Polymorphic or mutational markers
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
Applicants
  • 서울대학교병원 SEOUL NATIONAL UNIVERSITY HOSPITAL [KR]/[KR]
Inventors
  • 김나영 KIM, Nayoung
Agents
  • 최우성 CHOI, Woo-sung
Priority Data
10-2020-008561410.07.2020KR
10-2020-010196713.08.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) COMPOSITION COMPRISING MUC4 GENE MUTATION DETECTING AGENT FOR PREDICTION OR DIAGNOSIS OF GASTRIC CANCER
(FR) COMPOSITION COMPRENANT UN AGENT DE DÉTECTION DE MUTATION DU GÈNE MUC4 POUR LA PRÉDICTION OU LE DIAGNOSTIC DU CANCER GASTRIQUE
(KO) MUC4 유전자의 돌연변이 검출 제제를 포함하는 위암 예측 또는 진단용 조성물
front page image
Abstract
(EN) The present invention in which a MUC4 gene is discovered as a biomarker for predicting or diagnosis gastric cancer relates to a composition and kit capable of predicting or diagnosing gastric cancer when a mutation is present on the gene and to a method for providing information therefor. The composition according to an aspect of the present invention allows the detection of a mutation at one or more loci selected from the group consisting of rs774527434, rs534579185, rs77250903, rs868067409, rs531395109, rs754808151, rs1304612772, rs774907241, rs771925912, rs745342765, rs148735556, rs11717039, and rs547775645 on MUC4 gene, thus exhibiting an excellent effect of predicting or diagnosing gastric cancer in a cost and time effective manner for multiple subjects to be tested.
(FR) La présente invention dans laquelle un gène MUC4 est découvert en tant que biomarqueur de prédiction ou de diagnostic du cancer gastrique concerne une composition et un kit capable de prédire ou de diagnostiquer le cancer gastrique lorsqu'une mutation est présente sur le gène et un procédé de fourniture d'informations à cet effet. La composition selon un aspect de la présente invention permet la détection d'une mutation au niveau d'un ou plusieurs loci sélectionnés dans le groupe constitué de rs774527434, rs534579185, rs77250903, rs868067409, rs531395109, rs754808151, rs1304612772, rs774907241, rs771925912, rs745342765, rs148735556, rs11717039, et rs547775645 sur le gène MUC4, faisant ainsi preuve d'un excellent effet de prédiction ou de diagnostic du cancer gastrique d'une manière rentable et efficace pour de multiples sujets à tester.
(KO) 본 발명은 위암을 예측 또는 진단하기 위한 바이오마커로 MUC4 유전자를 발굴하고, 상기 유전자에 돌연변이가 있는 경우 위암을 예측 또는 진단할 수 있는 조성물, 키트 및 정보제공방법에 관한 것으로, 본 발명의 일 측면에 따른 조성물은 MUC4 유전자의 rs774527434, rs534579185, rs77250903, rs868067409, rs531395109, rs754808151, rs1304612772, rs774907241, rs771925912, rs745342765, rs148735556, rs11717039 및 rs547775645로 이루어진 군으로부터 선택된 하나 이상의 영역에서 돌연변이를 검출하여 다수의 피험자를 대상으로 비용 및 시간 효율적으로 위암을 예측 또는 진단할 수 있는 우수한 효과가 있다.
Related patent documents
KR102281058
KR1020220007566
Latest bibliographic data on file with the International Bureau
# -